Table 3.

Comparison of in-hospital medical and surgical outcomes before and after implementation of specialized inpatient IBD care

Outcome	Year 1 (General gastroenterology care) (n= 196)	Year 2 (Specialized IBD care) (n= 212)	p-value
Length of stay (in days) (Mean(SD))	6.4 (5.6)	7.2 (6.1)	0.17
Use of intravenous corticosteroids	60	51	0.09
New initiation of biologic therapy	23	16	0.11
Time to new biologic initiation (in days) (mean (SD))	5.7 (4.7)	5.6 (5.1)	0.95
Accelerated biologic dose†	4	13	0.24
High-dose biologic therapy†	9	26	0.04*
New initiation of IMM	7	6	0.84
Cyclosporine therapy	0.5	1	1.00
Antiviral therapy	5	2	0.08
Any IBD-related surgical procedure	13	19	0.07
Time to surgery (in days) (mean(SD))	7.6 (5.6)	4.5 (5.7)	0.04*
Bowel resection	6	7	0.84
Time to resection (in days) (mean(SD))	9.8 (5.0)	9.1 (7.4)	0.77
Time to non-resective operative intervention (in days) (mean(SD))	5.3 (1.6)	2.1 (2.1)	0.01

All figures represent percentages unless indicated otherwise

SD – standard deviation; IMM – immunomodulator

^†- Among those receiving biologic therapy

^*p ≤ 0.05